API | fenretinide

fenretinide Report issue

Biologics Peptide Experimental

Active Ingredient History

NOW

Fenretinide (N-(4-hydroxyphenyl)retinamide; 4-HPR) (INN) is a synthetic retinoid derivative. Retinoids are substances related to vitamin A. It has been investigated for potential use in the treatment of cancer, as well as in the treatment of cystic fibrosis, rheumatoid arthritis, acne, psoriasis, and has been found to also slow the production and accumulation of a toxin that leads to vision loss in Stargardt's patients. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

COVID-19 (Phase 2/Phase 3)

Cystic Fibrosis (Phase 2)

Lymphoma, Follicular (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Mycosis Fungoides (Phase 1)

Pharmacological and Toxicological Phenomena (Phase 1)

Sezary Syndrome (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue